{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Positron+Emission+Tomography+combined+with+Magnetic+resonance+imaging+%28PET%2FMRI%29&page=2", "query": { "intervention": "Positron Emission Tomography combined with Magnetic resonance imaging (PET/MRI)", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 158, "total_pages": 16, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Positron+Emission+Tomography+combined+with+Magnetic+resonance+imaging+%28PET%2FMRI%29&page=3&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Positron+Emission+Tomography+combined+with+Magnetic+resonance+imaging+%28PET%2FMRI%29&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-10T12:22:04.451Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00001337", "title": "Dose-Adjusted EPOCH Chemotherapy and Rituximab (CD20+) in Previously Untreated Aggressive Non-Hodgkin's Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Diffuse Large B-Cell Lymphoma (DLBCL)", "Primary Mediastinal Large B-cell Lymphoma", "Burkitt Lymphoma", "Anaplastic Large-Cell Lymphoma", "Gray Zone Lymphoma" ], "interventions": [ { "name": "Etoposide", "type": "DRUG" }, { "name": "Rituximab", "type": "BIOLOGICAL" }, { "name": "Prednisone", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Vincristine", "type": "DRUG" }, { "name": "Doxorubicin", "type": "DRUG" }, { "name": "MRI", "type": "DIAGNOSTIC_TEST" }, { "name": "CT", "type": "DIAGNOSTIC_TEST" }, { "name": "Biopsy", "type": "PROCEDURE" }, { "name": "PET scan", "type": "DIAGNOSTIC_TEST" }, { "name": "Laparotomy", "type": "PROCEDURE" }, { "name": "Ondansetron", "type": "OTHER" }, { "name": "Prochlorperazine", "type": "OTHER" }, { "name": "Omeprazole", "type": "OTHER" }, { "name": "Docusate Sodium + Sennosides", "type": "OTHER" }, { "name": "Lactulose", "type": "OTHER" } ], "intervention_types": [ "DRUG", "BIOLOGICAL", "DIAGNOSTIC_TEST", "PROCEDURE", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": null, "sex": "ALL", "summary": "12 Years and older" }, "enrollment_count": 348, "start_date": "1993-05-08", "completion_date": "2024-05-24", "has_results": true, "last_update_posted_date": "2025-06-22", "last_synced_at": "2026-10-10T12:22:04.451Z", "location_count": 5, "location_summary": "Fort Lauderdale, Florida • Baltimore, Maryland • Bethesda, Maryland + 2 more", "locations": [ { "city": "Fort Lauderdale", "state": "Florida" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Bethesda", "state": "Maryland" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00001337" }, { "nct_id": "NCT05050162", "title": "Comparing Cisplatin Every Three Weeks to Cisplatin Weekly When Combined With Radiation for Patients With Advanced Head and Neck Cancer", "overall_status": "SUSPENDED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Advanced Head and Neck Squamous Cell Carcinoma", "Advanced Hypopharyngeal Squamous Cell Carcinoma", "Advanced Laryngeal Squamous Cell Carcinoma", "Advanced Oropharyngeal Squamous Cell Carcinoma", "Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8", "Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8", "Stage III Head and Neck Cutaneous Squamous Cell Carcinoma AJCC v8", "Stage III Oropharyngeal (p16-Negative) Carcinoma AJCC v8", "Stage IV Head and Neck Cutaneous Squamous Cell Carcinoma AJCC v8", "Stage IV Oropharyngeal (p16-Negative) Carcinoma AJCC v8" ], "interventions": [ { "name": "Cisplatin", "type": "DRUG" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Positron Emission Tomography", "type": "PROCEDURE" }, { "name": "Quality-of-Life Assessment", "type": "OTHER" }, { "name": "Questionnaire Administration", "type": "OTHER" }, { "name": "Radiation Therapy", "type": "RADIATION" } ], "intervention_types": [ "DRUG", "PROCEDURE", "OTHER", "RADIATION" ], "sponsor": "NRG Oncology", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1714, "start_date": "2022-02-01", "completion_date": "2027-02-09", "has_results": false, "last_update_posted_date": "2026-06-25", "last_synced_at": "2026-10-10T12:22:04.451Z", "location_count": 361, "location_summary": "Mobile, Alabama • Jonesboro, Arkansas • Little Rock, Arkansas + 264 more", "locations": [ { "city": "Mobile", "state": "Alabama" }, { "city": "Jonesboro", "state": "Arkansas" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Anaheim", "state": "California" }, { "city": "Antioch", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05050162" }, { "nct_id": "NCT06649812", "title": "Testing the Effectiveness of a Combination Targeted Therapy (ViPOR) for Patients With Relapsed and/or Refractory Aggressive B-cell Lymphoma", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "High Grade B-Cell Lymphoma With MYC and BCL6 Rearrangements", "Recurrent Diffuse Large B-Cell Lymphoma", "Recurrent Diffuse Large B-Cell Lymphoma Germinal Center B-Cell Type", "Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified", "Recurrent High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements", "Recurrent High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements", "Recurrent High Grade B-Cell Lymphoma, Not Otherwise Specified", "Recurrent T-Cell/Histiocyte-Rich Large B-Cell Lymphoma", "Refractory Diffuse Large B-Cell Lymphoma", "Refractory Diffuse Large B-Cell Lymphoma Germinal Center B-Cell Type", "Refractory Diffuse Large B-Cell Lymphoma, Not Otherwise Specified", "Refractory High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements", "Refractory High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements", "Refractory High Grade B-Cell Lymphoma, Not Otherwise Specified", "Refractory T-Cell/Histiocyte-Rich Large B-Cell Lymphoma" ], "interventions": [ { "name": "Biopsy Procedure", "type": "PROCEDURE" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Bone Marrow Aspiration", "type": "PROCEDURE" }, { "name": "Bone Marrow Biopsy", "type": "PROCEDURE" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Ibrutinib", "type": "DRUG" }, { "name": "Lenalidomide", "type": "DRUG" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Obinutuzumab", "type": "BIOLOGICAL" }, { "name": "Positron Emission Tomography", "type": "PROCEDURE" }, { "name": "Prednisone", "type": "DRUG" }, { "name": "Venetoclax", "type": "DRUG" } ], "intervention_types": [ "PROCEDURE", "DRUG", "BIOLOGICAL" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 120, "start_date": "2025-10-07", "completion_date": "2028-09-01", "has_results": false, "last_update_posted_date": "2026-10-07", "last_synced_at": "2026-10-10T12:22:04.451Z", "location_count": 113, "location_summary": "Tucson, Arizona • Los Angeles, California • Derby, Connecticut + 92 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Derby", "state": "Connecticut" }, { "city": "Guilford", "state": "Connecticut" } ], "official_url": "https://clinicaltrials.gov/study/NCT06649812" }, { "nct_id": "NCT07783581", "title": "Proton Spatially Fractionated Radiotherapy or Photon Stereotactic Body Radiotherapy in Combination With Pembrolizumab Before Surgery for the Treatment of Locally Advanced and Radiation-Naive Locoregionally Recurrent Oral Cavity Cancer, OSPRI Trial", "overall_status": "NOT_YET_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Locally Advanced Oral Cavity Squamous Cell Carcinoma", "Locally Recurrent Oral Cavity Squamous Cell Carcinoma", "Oral Cavity Squamous Cell Carcinoma" ], "interventions": [ { "name": "Biopsy Procedure", "type": "PROCEDURE" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Pembrolizumab", "type": "BIOLOGICAL" }, { "name": "Photon Stereotactic Body Radiation Therapy", "type": "RADIATION" }, { "name": "Positron Emission Tomography", "type": "PROCEDURE" }, { "name": "Spatially-fractionated Radiation Therapy", "type": "RADIATION" }, { "name": "Surgical Procedure", "type": "PROCEDURE" } ], "intervention_types": [ "PROCEDURE", "BIOLOGICAL", "RADIATION" ], "sponsor": "Mayo Clinic", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 30, "start_date": "2026-09-07", "completion_date": "2030-04-01", "has_results": false, "last_update_posted_date": "2026-08-25", "last_synced_at": "2026-10-10T12:22:04.451Z", "location_count": 1, "location_summary": "Rochester, Minnesota", "locations": [ { "city": "Rochester", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT07783581" }, { "nct_id": "NCT02567422", "title": "Testing the Addition of M6620 (VX-970, Berzosertib) to Usual Chemotherapy and Radiation for Head and Neck Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Head and Neck Carcinoma of Unknown Primary", "Head and Neck Squamous Cell Carcinoma", "Stage III Hypopharyngeal Squamous Cell Carcinoma AJCC v7", "Stage III Laryngeal Squamous Cell Carcinoma AJCC v6 and v7", "Stage III Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7", "Stage III Oropharyngeal Squamous Cell Carcinoma AJCC v7", "Stage III Sinonasal Squamous Cell Carcinoma AJCC v6 and v7", "Stage IV Hypopharyngeal Squamous Cell Carcinoma AJCC v7", "Stage IV Laryngeal Squamous Cell Carcinoma AJCC v7", "Stage IV Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7", "Stage IV Oropharyngeal Squamous Cell Carcinoma AJCC v7", "Stage IV Sinonasal Squamous Cell Carcinoma AJCC v7" ], "interventions": [ { "name": "Berzosertib", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Positron Emission Tomography", "type": "PROCEDURE" }, { "name": "Radiation Therapy", "type": "RADIATION" } ], "intervention_types": [ "DRUG", "PROCEDURE", "OTHER", "RADIATION" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 43, "start_date": "2017-04-17", "completion_date": "2027-05-14", "has_results": true, "last_update_posted_date": "2026-07-31", "last_synced_at": "2026-10-10T12:22:04.451Z", "location_count": 19, "location_summary": "Duarte, California • Sacramento, California • New Haven, Connecticut + 13 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Sacramento", "state": "California" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Trumbull", "state": "Connecticut" } ], "official_url": "https://clinicaltrials.gov/study/NCT02567422" }, { "nct_id": "NCT07275216", "title": "Pembrolizumab in Combination With Chemotherapy for the Treatment of Frail Hodgkin Lymphoma Patients Ineligible for Standard Treatment", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Classic Hodgkin Lymphoma" ], "interventions": [ { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Brentuximab Vedotin", "type": "DRUG" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Dacarbazine", "type": "DRUG" }, { "name": "Echocardiography Test", "type": "PROCEDURE" }, { "name": "Gemcitabine", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "BIOLOGICAL" }, { "name": "Physical Performance Testing", "type": "OTHER" }, { "name": "Positron Emission Tomography", "type": "PROCEDURE" }, { "name": "Pulmonary Function Test", "type": "PROCEDURE" } ], "intervention_types": [ "PROCEDURE", "DRUG", "BIOLOGICAL", "OTHER" ], "sponsor": "City of Hope Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 23, "start_date": "2026-10-01", "completion_date": "2029-10-20", "has_results": false, "last_update_posted_date": "2026-08-20", "last_synced_at": "2026-10-10T12:22:04.451Z", "location_count": 1, "location_summary": "Duarte, California", "locations": [ { "city": "Duarte", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT07275216" }, { "nct_id": "NCT06169124", "title": "Study to Test the Drug Darolutamide Along With the Drugs Leuprolide Acetate and Exemestane in Patients With Recurrent Ovarian Granulosa Cell Tumors", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Adult Ovarian Granulosa Cell Tumor" ], "interventions": [ { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Chest Radiography", "type": "PROCEDURE" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Darolutamide", "type": "DRUG" }, { "name": "Exemestane", "type": "DRUG" }, { "name": "Leuprolide Acetate", "type": "DRUG" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Positron Emission Tomography", "type": "PROCEDURE" } ], "intervention_types": [ "PROCEDURE", "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 17, "start_date": "2024-02-08", "completion_date": "2027-07-24", "has_results": false, "last_update_posted_date": "2026-07-28", "last_synced_at": "2026-10-10T12:22:04.451Z", "location_count": 66, "location_summary": "Los Angeles, California • Newark, Delaware • Boise, Idaho + 55 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Newark", "state": "Delaware" }, { "city": "Newark", "state": "Delaware" }, { "city": "Boise", "state": "Idaho" }, { "city": "Caldwell", "state": "Idaho" } ], "official_url": "https://clinicaltrials.gov/study/NCT06169124" }, { "nct_id": "NCT05627635", "title": "FOLFOX and Bevacizumab in Combination With Botensilimab and Balstilimab (3B-FOLFOX) for the Treatment of Microsatellite Stable (MSS) Metastatic Colorectal Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Metastatic Colon Adenocarcinoma", "Metastatic Colorectal Adenocarcinoma", "Metastatic Microsatellite Stable Colorectal Carcinoma", "Metastatic Rectal Adenocarcinoma", "Stage IV Colon Cancer AJCC v8", "Stage IV Colorectal Cancer AJCC v8", "Stage IV Rectal Cancer AJCC v8" ], "interventions": [ { "name": "Balstilimab", "type": "BIOLOGICAL" }, { "name": "Bevacizumab", "type": "BIOLOGICAL" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Botensilimab", "type": "BIOLOGICAL" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Fluorouracil", "type": "DRUG" }, { "name": "Leucovorin Calcium", "type": "DRUG" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Oxaliplatin", "type": "DRUG" }, { "name": "Positron Emission Tomography", "type": "PROCEDURE" }, { "name": "X-Ray Imaging", "type": "PROCEDURE" } ], "intervention_types": [ "BIOLOGICAL", "PROCEDURE", "DRUG" ], "sponsor": "City of Hope Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 20, "start_date": "2023-05-03", "completion_date": "2027-06-16", "has_results": false, "last_update_posted_date": "2026-09-01", "last_synced_at": "2026-10-10T12:22:04.451Z", "location_count": 1, "location_summary": "Duarte, California", "locations": [ { "city": "Duarte", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05627635" }, { "nct_id": "NCT06096844", "title": "Chemotherapy Combined With Immunotherapy Versus Immunotherapy Alone for Older Adults With Stage IIIB-IV Lung Cancer, The ACHIEVE Trial", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Advanced Lung Non-Small Cell Carcinoma", "Stage IIIB Lung Cancer AJCC v8", "Stage IIIC Lung Cancer AJCC v8", "Stage IV Lung Cancer AJCC v8" ], "interventions": [ { "name": "Carboplatin", "type": "DRUG" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Nab-paclitaxel", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "BIOLOGICAL" }, { "name": "Pemetrexed", "type": "DRUG" }, { "name": "Positron Emission Tomography", "type": "PROCEDURE" }, { "name": "Questionnaire Administration", "type": "OTHER" } ], "intervention_types": [ "DRUG", "PROCEDURE", "BIOLOGICAL", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "70 Years", "maximum_age": null, "sex": "ALL", "summary": "70 Years and older" }, "enrollment_count": 304, "start_date": "2024-07-19", "completion_date": "2039-04-01", "has_results": false, "last_update_posted_date": "2026-10-08", "last_synced_at": "2026-10-10T12:22:04.451Z", "location_count": 326, "location_summary": "Fayetteville, Arkansas • Fort Smith, Arkansas • Rogers, Arkansas + 256 more", "locations": [ { "city": "Fayetteville", "state": "Arkansas" }, { "city": "Fort Smith", "state": "Arkansas" }, { "city": "Rogers", "state": "Arkansas" }, { "city": "Springdale", "state": "Arkansas" }, { "city": "Dublin", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT06096844" }, { "nct_id": "NCT05272384", "title": "Testing the Combination of Nivolumab and ASTX727 for Relapsed or Refractory B-Cell Lymphoma", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Recurrent B-Cell Non-Hodgkin Lymphoma", "Recurrent Diffuse Large B-Cell Lymphoma", "Recurrent Hodgkin Lymphoma", "Refractory B-Cell Non-Hodgkin Lymphoma", "Refractory Diffuse Large B-Cell Lymphoma", "Refractory Hodgkin Lymphoma" ], "interventions": [ { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Decitabine and Cedazuridine", "type": "DRUG" }, { "name": "Nivolumab", "type": "BIOLOGICAL" }, { "name": "Positron Emission Tomography", "type": "PROCEDURE" } ], "intervention_types": [ "PROCEDURE", "DRUG", "BIOLOGICAL" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 32, "start_date": "2022-11-03", "completion_date": "2027-06-28", "has_results": false, "last_update_posted_date": "2026-09-10", "last_synced_at": "2026-10-10T12:22:04.451Z", "location_count": 9, "location_summary": "Birmingham, Alabama • Duarte, California • Sacramento, California + 6 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Duarte", "state": "California" }, { "city": "Sacramento", "state": "California" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT05272384" } ] }